Showing 21 - 40 results of 112 for search 'testosterone (medication)', query time: 0.07s Refine Results
  1. 21
  2. 22
  3. 23
  4. 24
  5. 25
  6. 26
  7. 27

    Abnormalities in Blood Parameters in Athletes Taking Anabolic Androgenic Steroidal Agents; an Observational Clinical Study by Mubarak GS, Bamagous GA, Alsanosi SM, Alhindi YZ, Alqashqari HS, Albar HT, Siddiqi AM, Ayoub N, Falemban AH

    Published 2025-01-01
    “…The most used combination was testosterone plus growth hormone (45%), and the most used supplements were liver protectors (84%). …”
    Get full text
    Article
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34

    Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer by Kelly Gaudian, Min Jung Koh, Min Ji Koh, Ryan R. Collins, Shaine Eden, Zoya Zwart, Malika Danner, Alan Zwart, Mark Fallick, Deepak Kumar, Paul Leger, Nancy A. Dawson, Simeng Suy, Sean P. Collins

    Published 2025-01-01
    “…Relugolix is an oral GnRH receptor antagonist that achieves rapid testosterone suppression. Non-adherence to oral medications due to poor social support or bothersome side effects may increase the risk of cancer recurrence. …”
    Get full text
    Article
  15. 35

    The value of sex hormones and sex hormone-binding globulin in metabolic dysfunction-associated fatty liver disease among boys with obesity by Ying Wang, Shuyi Yang, Suming Zhang, Suming Zhang, Ye Yang, Siqing Li, Siqing Li, Meiyu Zhang, Meiyu Zhang, Xiaona Li, Hua Bai, Peiliang Luo, Yingdi Yuan, Yingdi Yuan

    Published 2025-02-01
    “…Logistic regression showed that BMI, testosterone, and SHBG were independent risk factors for MAFLD in boys, and ROC curve analysis indicated their potential value in the early diagnosis of MAFLD.ConclusionBMI, testosterone, and SHBG are independent risk factors for the occurrence of MAFLD in boys with obesity. …”
    Get full text
    Article
  16. 36
  17. 37
  18. 38
  19. 39
  20. 40